drugset / Trial / NCT00773591

Effect of NT 201 (Botulinum Neurotoxin Type A Free of Complexing Proteins) on Sleep-related Breathing Disorders

NCT00773591

Phase 2 Withdrawn Merz Pharmaceuticals GmbH
RandomizedParallel-groupDouble-blindTreatment

Summary

This proof-of-concept study is to assess the potential benefit of botulinum toxin for patients with sleep-related breathing disorders.

Timeline

Start
2010-03
Primary completion
2010-10
Completion
2010-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Botulinum toxin type A Protein / enzyme biologic 5 iu Other

Indications